ICON Public Limited (NASDAQ:ICLR) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of ICON Public Limited (NASDAQ:ICLR) have been given an average recommendation of “Moderate Buy” by the fifteen ratings firms that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have covered the stock in the last year is $281.00.

A number of brokerages recently commented on ICLR. Leerink Partners reaffirmed an “outperform” rating and issued a $255.00 target price (down from $270.00) on shares of ICON Public in a report on Tuesday, November 19th. Truist Financial reduced their price objective on shares of ICON Public from $284.00 to $262.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $263.00 target price on shares of ICON Public in a report on Wednesday, January 15th. JPMorgan Chase & Co. lowered their price objective on ICON Public from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. Finally, William Blair reissued an “outperform” rating on shares of ICON Public in a research note on Tuesday, January 14th.

ICON Public Trading Down 0.8 %

NASDAQ:ICLR opened at $197.50 on Friday. The company has a market cap of $16.29 billion, a PE ratio of 20.72, a price-to-earnings-growth ratio of 1.86 and a beta of 1.19. ICON Public has a 12 month low of $181.51 and a 12 month high of $347.72. The company has a current ratio of 1.26, a quick ratio of 1.34 and a debt-to-equity ratio of 0.36. The company has a 50 day simple moving average of $202.69 and a two-hundred day simple moving average of $242.86.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.41 by $0.01. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. The business had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.04 billion. Research analysts forecast that ICON Public will post 13.38 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Foyston Gordon & Payne Inc purchased a new position in ICON Public during the 3rd quarter worth approximately $11,672,000. Kornitzer Capital Management Inc. KS lifted its holdings in ICON Public by 40.6% in the fourth quarter. Kornitzer Capital Management Inc. KS now owns 97,102 shares of the medical research company’s stock valued at $20,363,000 after acquiring an additional 28,050 shares during the period. Icon Wealth Advisors LLC boosted its holdings in ICON Public by 861.1% during the third quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock worth $3,797,000 after buying an additional 11,840 shares in the last quarter. Natixis Advisors LLC grew its position in ICON Public by 6.7% during the fourth quarter. Natixis Advisors LLC now owns 177,761 shares of the medical research company’s stock valued at $37,279,000 after buying an additional 11,177 shares during the period. Finally, Entropy Technologies LP grew its position in ICON Public by 472.2% during the fourth quarter. Entropy Technologies LP now owns 6,174 shares of the medical research company’s stock valued at $1,295,000 after buying an additional 5,095 shares during the period. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.